With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.655225-01-7,tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.,655225-01-7
Intermediate 22: 1 ,1-Dimethylethyl 4-{2-r6-amino-2-(butyloxy)-8-(methyloxy)-9H- purin-9-yl1ethyl)-1-piperazinecarboxylate; 2-(Butyloxy)-8-(methyloxy)-9H-purin-6-amine trifluoroacetate (131 mg, 0.373mmole) and potassium carbonate (185mg, 0.41 mmole) in DMF (1 ml) was stirred and heated at 60¡ãC for 1 hour. A solution of 1 ,1-dimethylethyl 4-(2-bromoethyl)-1- piperazinecarboxylate (120mg, 0.41 mmole) in DMF (0.6ml) was added and the mixture stirred at 500C for 2.5 hours and then left at room temperature overnight. The mixture was heated at 500C for a further 4 hours and then quenched with water (10ml) and extracted with ethyl acetate (3×1 OmI). The combined organic extracts were dried over anhydrous sodium sulphate, filtered and evaporated. The residue was purified by silica gel chromatography eluting initially with chloroform:methanol 90:1 then 80:1 then 75:1 and finaly 60:1. Product-containing fractions were combined and evaporated to give the title compound as a yellow oily solid (168mg). 1H NMR (CDCI3): delta 5.66 (2H, d), 4.25 (2H, t), 4.05 (2H, t), 4.10 (3H, s), 3.35 (4H, broad s), 2.71 (2H, t), 2.46 (4H, broad s) 1.76 (2H, q) 1.48 (2H, q), 1.45 (9H, s) and 0.96 (3H, t).
The synthetic route of 655225-01-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; BAZIN-LEE, Helene; BIGGADIKE, Keith; COE, Diane, Mary; LEWELL, Xiao, Qing; MITCHELL, Charlotte, Jane; TRIVEDI, Naimisha; WO2010/18131; (2010); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics